louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02518334: Wine Consumption and Glycemic Control
Official title: Wine Consumption and Glycemic Control
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 2
Keywords: type two diabetes
glycemic control
Lead sponsor: University of Missouri-Columbia
Sponsor class: OTHER
First posted: 2015-08-07
Enrollment: 14
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Many studies have reported that alcoholic beverage consumption, especially in the form of wine, reduces the risk of developing type 2 diabetes by as much as 40%. This association suggests that wine consumption may somehow improve the body's ability to control its blood glucose concentration. Indeed, it has been reported that when wine is consumed immediately prior to ingestion of glucose, the release of insulin is enhanced and blood glucose concentration is lowered. The mechanism of wine's effects on blood glucose concentration is unknown, but is likely related to its ethanol or antioxidant content. In this study, the investigators plan to test whether wine or plain ethanol (vodka) ingestion alters the control of blood glucose in subjects who have diabetes or pre-diabetes.

Detailed description: Our central hypothesis is that improvement in glycemic control by acute consumption of wine is mediated by ethanol. Subjects will have type 2 diabetes, pre-diabetes, and be sedentary and obese (BMI \>30). Subjects' glycemic control will be assessed by an oral glucose tolerance test (OGTT) at three different time points. One OGTT will occur shortly after consumption of red wine, the second after consumption of vodka containing the identical amount of ethanol as the wine treatment, and the third OGTT will occur shortly after consumption of an equal volume of water. The three OGTTs will be administered in random order.

Eligibility criteria: Inclusion Criteria:

* insulin resistant: diagnosed with pre-diabetes or fasting blood glucose \>/= 97 mg/dL
* T2D: diagnosed by primary care physician
* at risk of type 2 diabetes (obesity and physically inactive)
* age: 21-65

Exclusion Criteria:

* smoking
* insulin use (other than once daily)
* physically active (\>30 mins aerobic exercise two days/week)
* recent (\>3 mo) changes in medication use or dose
* uncontrolled type two diabetes (HbA1C \>10%)
* advanced retinopathy or neuropathy
* pregnancy

Primary outcomes:
measure: Oral glucose tolerance test
timeFrame: 3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Columbia
country: United States
facility: University of Missouri
state: Missouri
Study officials:
affiliation: University of Missouri-Columbia
name: John P Thyfault, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Avogaro A, Watanabe RM, Dall'Arche A, De Kreutzenberg SV, Tiengo A, Pacini G. Acute alcohol consumption improves insulin action without affecting insulin secretion in type 2 diabetic subjects. Diabetes Care. 2004 Jun;27(6):1369-74. doi: 10.2337/diacare.27.6.1369.
Clinical trial NCT02132117: Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Erythema
Rosacea
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2014-05-07
Enrollment: 445
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety and efficacy of oxymetazoline hydrochloride (HCl) cream 1.0% (AGN-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.


Eligibility criteria: Inclusion Criteria:

-Moderate to severe persistent facial erythema associated with rosacea.

Exclusion Criteria:

* Greater than 3 inflammatory lesions on the face
* Current treatment with monoamine oxidase (MAO) inhibitors
* Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.

Primary outcomes:
measure: Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for Rosacea Facial Redness (SSA) 5-point Scales
timeFrame: Baseline, Day 29 (Hours 3, 6, 9 and 12)
Secondary outcomes:
measure: Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on SSA at Hours 3, 6, 9 and 12 on Day 29
timeFrame: Baseline, Day 29 (Hours 3, 6, 9 and 12)
measure: Percent Change From Baseline on Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA) at Hours 3, 6, 9 and 12 on Day 29
timeFrame: Baseline, Day 29 (Hours 3, 6, 9 and 12)
measure: Percentage of Participants Satisfied or Very Satisfied on Item #9 of Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR) at Hours 3, 6, 9 and 12 on Day 29
timeFrame: Day 29 (Hours 3, 6, 9 and 12)
measure: Change From Baseline on the Symptom Assessment for Rosacea Facial Redness (SA-RFR) Item # 4 at Hours 3, 6, 9 and 12 on Day 29
timeFrame: Baseline, Day 29 (Hours 3, 6, 9 and 12)
measure: Percentage of Participants With at Least a 1-Grade Improvement (Decrease) From Baseline on SSA at Hour 1 on Day 1
timeFrame: Baseline, Day 1 (Hour 1)
Other outcomes:
Locations:
city: College Station
country: United States
state: Texas
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT05097417: Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer
Official title: A Prospective Open-Label Randomized Study of Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Non-small Cell Lung Cancer Stage I
Lead sponsor: Shanghai 10th People's Hospital
Sponsor class: OTHER
First posted: 2021-10-28
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Lung cancer is the leading cause of cancer related mortality. At present, surgical treatment is the main choice for early-stage lung cancer. Even after surgery, the 5-year recurrence rate is still as high as 18.4%-24%. Traditional Chinese medicine combined with thermal and cold ablation could be an alternative treatment. Small sample clinical cases verified that this therapy could be an efficacy and safe treatment in a short period. The primary aim of this trial is to evaluate the efficacy of traditional Chinese medicine combined with thermal and cold ablation for patients with stage I non-small cell lung cancer.


Eligibility criteria: Inclusion Criteria:

* The patient can understand and voluntarily join the study, sign the informed consent form, and the compliance is good.
* Patients with lung nodule.
* Maximum diameter of lung nodule ≥8mm.
* The pathology of lung nodules biopsy was non-small cell lung cancer.
* I period according to the eighth edition of the TNM staging period.
* No mediastinal lymph node metastasis.
* Eastern Cooperative Oncology Group performance status of 0 to 1.
* No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments.
* Sufficient organ functions.

Exclusion Criteria:

* Patients with previous use of various hormones, immunosuppression or autoimmune diseases.
* Women during pregnancy or breast-feeding.
* Patients with severe heart, lung, kidney disease or other systemic diseases
* Patients with severe hemorrhagic diseases.
* Patients with a history of drug abuse or mental illness.
* Other conditions that the investigator has determined are not suitable for participation in this study

Primary outcomes:
measure: Objective Response Rate (ORR)
timeFrame: 2 years after ablation
Secondary outcomes:
measure: DFS
timeFrame: 2 years after ablation
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai 10th People's Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT06719817: Evaluation of Some Trace Elements in Follicular Fluid in ICSI Cases and Their Effect on ICSI Outcomes
Official title: Evaluation of Some Trace Elements in Follicular Fluid in Intracytoplasmic Sperm Injection(ICSI) Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Good Responders According to Guidelines Who Wre Charectarized by AMH>0.8ng/dl
Trace Elements in ICSI Cases
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-12-06
Enrollment: 154
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: good responders according to NICE guidelines with AMH more than 0.8ng/dl and antral follicular count more than 4

Brief summary: To evaluate concentrations of some trace elements in the follicular fluid and their reproductive outcomes.

Detailed description: To evaluate some trace elements in the follicular fluid and their reproductive outcome

Eligibility criteria: Inclusion Criteria:good responders according to NICE guidelines with AMH more than 0.8ng/dl and antral follicular count more than 4 Exclusion Criteria:Poor responders according to ESHRE guidelines as advanced maternal age poor ovarian response and according to NICE guidelines AMH less than 0.8ng/dl

Primary outcomes:
measure: oocyte maturity
timeFrame: 2024 to 2026
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Faculty of medicine
city: Assiut
country: Egypt
facility: Faculty of medicine
Study officials:
References:
Clinical trial NCT04255017: A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
Official title: An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: 2019-nCoV
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2020-02-05
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by new coronavirus infection.


Eligibility criteria: Inclusion Criteria:

1. 2019-nCoV nucleic acid test was positive.
2. CT of the lung conformed to the manifestation of viral pneumonia.

Exclusion Criteria:

1. Patients who meet any of the contraindications in the experimental drug labeling
2. Patients who do not want to participate in this clinical study

Primary outcomes:
measure: Rate of disease remission
timeFrame: two weeks
measure: Time for lung recovery
timeFrame: two weeks
Secondary outcomes:
measure: Rate of no fever
timeFrame: two weeks
measure: Rate of respiratory symptom remission
timeFrame: two weeks
measure: Rate of lung imaging recovery
timeFrame: two weeks
measure: Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery
timeFrame: two weeks
measure: Rate of undetectable viral RNA
timeFrame: two weeks
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Department and Institute of Infectious Disease
state: Hubei
Study officials:
References:
Clinical trial NCT02583217: Effect of Ketamine+Propofol vs Remifentanyl+Propofol on Laryngeal Mask Insertion Conditions
Official title: Effect of Ketamine+Propofol vs Remifentanyl+Propofol on Laryngeal Mask Insertion Conditions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Surgery
Keywords: Laryngeal mask
Ketamine
Remifentanyl
Lead sponsor: Ankara University
Sponsor class: OTHER
First posted: 2015-10-22
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Surgery performed with laryngeal mask as airway tool in gynecologic clinic

Brief summary: Laryngeal mask airway is a common tool for airway management during anesthesia in many surgeries. Insertion of laryngeal mask needs deep anesthesia, suppression of airway, stabile hemodynamic response. Many drug regimens has been used for this purpose. This study aimed to compare the insertion conditions of laryngeal mask by using ketamine+propofol versus remifentanil + propofol.


Eligibility criteria: Inclusion Criteria:

* Surgery requires laryngeal mask

Exclusion Criteria:

* Patient refusal, abdominal surgery required muscle relaxant, any allergy to ketamine or remifentanyl

Primary outcomes:
measure: High laryngeal mask insertion scores
timeFrame: 3 minutes
Secondary outcomes:
measure: Hypotension
timeFrame: 10 minutes
measure: Hypertension
timeFrame: 10 minutes
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Cigdem Yildirim Guclu
Study officials:
affiliation: Ankara University
name: CIGDEM YILDIRIM GUCLU, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00000217: Pharmacotherapy and Intensive Treatment of Drug Abuse - 1
Official title: Pharmacotherapy and Intensive Treatment of Drug Abuse
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cocaine-Related Disorders
Substance-Related Disorders
Keywords: drug abuse
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
name: US Department of Veterans Affairs
First posted: 1999-09-21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.


Eligibility criteria: Please contact site for information.

Primary outcomes:
measure: Drug use
measure: Effectiveness of medication
measure: Level of pharm
measure: Retention
measure: Depression, anxiety
Secondary outcomes:
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: University of Kansas
state: Missouri
Study officials:
affiliation: University of Kansas
name: William Haning, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: J Addictive Dis. 13; 1994
Clinical trial NCT01279317: Vinegar Co-ingestion in Type 2 Diabetes
Official title: The Effect of Vinegar Co-ingestion on Postprandial Glucose Control in Type 2 Diabetes Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
First posted: 2011-01-19
Enrollment: 12
Sex: MALE
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The main objective of this study is to assess the acute effect of co-ingested vinegar on postprandial plasma glucose levels in type 2 diabetes patients.

Detailed description: Plasma glucose and insulin concentrations are assessed over the 2 hr period following ingestion of carbohydrate-rich beverage with or without added vinegar.

Eligibility criteria: Inclusion Criteria:

* male type 2 diabetes
* overweight or obese
* 40-70 yrs

Exclusion Criteria:

* incident cardiovascular events during last year
* peptic ulcer, duodenal ulcer, oesophageal reflux
* antacids, H2 receptor blocker, proton pump inhibitors, NSAIDS, prokinetic agents

Primary outcomes:
measure: Postprandial Glycemic Incremental Area Under the Curve
timeFrame: 2 hr
Secondary outcomes:
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Centre
state: Limburg
Study officials:
References:
Clinical trial NCT00239317: Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Urinary Tract Diseases
Keywords: tamsulosin
urinary tract diseases
male
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2005-10-17
Sex: MALE
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether Tamusulosin is effective in the treatment of lower urinary tract syndrome with male patients.


Eligibility criteria: Inclusion Criteria:

* Patients with urination disorder not accompanied by apparent organic or neurologic abnormality(lower urinary tract syndrome: LUTs).

Exclusion Criteria:

* Patients with urination disorder accompanied by apparent organic(benign prostatic hyperplasia: BPH) or neurologic abnormality, active urinary tract infections, severe cardiovascular, hepatic and/or kidney complications.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Chubu region
country: Japan
city: Chugoku region
country: Japan
city: Hokkaido region
country: Japan
city: Kanto region
country: Japan
city: Kinki region
country: Japan
city: Kyushu region
country: Japan
city: Touhoku region
country: Japan
Study officials:
affiliation: Clinical Development, Astellas Pharma Inc.
name: Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT04502017: Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion
Official title: Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Device-Related Thrombosis
Atrial Fibrillation
Left Atrial Appendage Occlusion
Keywords: left atrial appendage
Watchman
antithrombotic therapy
device-related thrombosis
Lead sponsor: Texas Cardiac Arrhythmia Research Foundation
Sponsor class: OTHER
First posted: 2020-08-06
Enrollment: 360
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Comparison among three different antithrombotic strategies after percutaneous LAA occlusion with a Watchman FLX LAAC device.

Detailed description: Data on the optimal antithrombotic therapy (AT) after percutaneous left atrial appendage (LAA) occlusion are still scarce. The classical AT strategy after LAA occlusion includes 6-weeks of warfarin + aspirin followed by dual anti platelet therapy with clopidogrel (75 mg) and aspirin (81-325 mg) until 6 months of follow-up, then aspirin alone is continued indefinitely. Nonetheless, a significant number of patients continues to suffer from device-related thrombosis which carries a high risk of thromboembolic events. Other AT strategies have been tested in order to reduce the risk of thrombus-formation on device. Among them, replacement of clopidogrel with half-dose oral anticoagulation (OAC) in patients with genetic resistance to this drug has been recently reported to reduce the incidence of DRT. Additionally, reduced dose of novel OAC was demonstrated to lead to lower thrombin generation compared to DAPT.

Eligibility criteria: Inclusion Criteria:

* Men and women ≥18 years of age
* Successful LAAC procedure (device implanted without procedural or bleeding complication).
* Patients contraindicated or unsuitable for long-term OAC.
* History of AF (permanent or persistent or paroxysmal).
* Written informed consent by the patient or designee if the patient is unable to consent

Exclusion Criteria:

* Life expectancy \< 2 years.
* Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

Primary outcomes:
measure: Composite of Stroke, Systemic Embolism, and Device-related Thrombosis
timeFrame: 1 year
measure: Incidence of Major Bleeding Events
timeFrame: 1 year
Secondary outcomes:
measure: Incidence of Minor Bleeding Events
timeFrame: 1 year
Other outcomes:
Locations:
city: Austin
country: United States
facility: St. David's Medical Center
state: Texas
Study officials:
References:
Clinical trial NCT06994117: Expanded Access for Mezigdomide
Study type: EXPANDED_ACCESS
Overall status: AVAILABLE
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2025-05-29
Standard ages: CHILD
ADULT
OLDER_ADULT

Brief summary: This is an expanded access designed to provide access to Mezigdomide for eligible participants.


Eligibility criteria: Inclusion Criteria:

-

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References: